EcoDrugPlus

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSUMAG00000016633
Gene Symbol: GRIA2
4 Cross references
320 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSUMAG00000023092
Gene Symbol: GRIA3
4 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSUMAG00000008904
Gene Symbol: GRIA4
4 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSUMAG00000003754
Gene Symbol: GRIN2A
4 Cross references
227 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSUMAG00000002456
Gene Symbol: GRIN2B
4 Cross references
330 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 3a

Ensembl ID : ENSUMAG00000013028
Gene Symbol: GRIN3A
2 Cross references
245 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 1

Ensembl ID : ENSUMAG00000016210
Gene Symbol: GRIK1
4 Cross references
302 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSUMAG00000020951
Gene Symbol: GRIK2
4 Cross references
331 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSUMAG00000001150
Gene Symbol: GRIK3
4 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSUMAG00000022880
Gene Symbol: GRIK4
4 Cross references
260 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSUMAG00000002670
Gene Symbol: GRIK5
4 Cross references
302 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSUMAG00000021663
Gene Symbol: GRM2
4 Cross references
276 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).